Circulation-Heart Failure

Article	Citations
Cognitive and Procedural Competencies in the Cardiac Intensive Care Unit	143
National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later	107
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation	104
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions	103
Characteristics of United States Counties in Which Heart Failure Clinical Trials of Pharmacotherapy Were Conducted	103
Letter by Qiu and Du Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	96
High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial	78
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	78
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion	73
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program	71
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance	65
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes	57
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	53
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	52
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System	52
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy	48
Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample	48
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	47
Prolonged Extreme Asymptomatic Hypertroponinemia as a Milestone in Diagnosis of Familial Arrhythmogenic Right Ventricular Cardiomyopathy	42
Ongoing Enigma of NT-proBNP in HFpEF: Insights From Proteomics	42
Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study	42
Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy	41
Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study	40
Letter by Baldovino et al Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	39
Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction	39

Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review	38
Rethinking Donor and Recipient Risk Matching in Europe and North America: Using Heart Transplant Predictors of Donor and Recipient Risk	37
Predicted Heart Mass: A Tale of 2 Ventricles	36
Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death	35
Rethinking the Nomenclature of Heart Failure Cardiogenic Shock: Do We Need to Start De Novo?	35
Trajectory of Cognitive Function After Incident Heart Failure	34
Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock	33
Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications	33
Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study	33
Incidence and Outcomes of Advanced Heart Failure in Adults With Congenital Heart Disease	32
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	31
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity	31
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State	30
Pressure Overload–Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone Apc Min Mice	30
Letter by Inker et al Regarding Article, “Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical	29
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury	29
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis	29
Letter by Hu Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	28
Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?	28
Peripheral Venous Pressure+Fenestration Doppler=Noninvasive Cardiac Catheterization Post-Fontan	28
Easing the Strain: Atrial Function After Atrial Shunting	28
Correction to: “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure”	28
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure	28
Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1	27
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark	27
Knowing All the Angles (on Right Ventricular Myocardial Remodeling)	27
Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation	27
Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction	27
Response by Prisco and Prins to Letter Regarding Article, “Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventri	27
Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF	26
Will the SGLT2i Responders Please Stand Up?	26
Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction	25
Single Arterial Access for VA-ECMO–Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve	25
Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry	24
Letter by Lim Regarding Article, “The Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the Danger Shock Trial?”	24
Letter by Kounis et al Regarding Article, “Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine”	24
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF	24
Response by Brahmbhatt et al to Letter Regarding Article, “Liberation From Venoarterial Extracorporeal Membrane Oxygenation: A Review”	24
Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea	24
Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality	24
Cardiomyopathy Across the Tree of Life: Insights for Clinicians and Investigators	24
Mucopolysaccharidosis Type IIIA Presenting as Hypertrophic Cardiomyopathy	24
Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure	23
Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay	23
PHM in Heart Transplantation: From Predicted Heart Mass to Practical Heart Matching	23
Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond	23
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial	23
Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis	23
Markets, Messaging, and Mastery: Reframing the Conversation Around the Heart Failure Physician Workforce	23
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF	22

Race, Sex, and Age Disparities in the Performance of ECG Deep Learning Models Predicting Heart Failure	22
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure	22
Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study	22
Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics	21
Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry	21
Unraveling the Pathophysiological Mechanisms of Phospholamban R14del Cardiomyopathy: A Comprehensive Overview	21
Response by Schlender et al to Letter Regarding Article, “Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support”	20
A Sweet Solution for Heart Failure With Preserved Ejection Fraction: The Role of Sodium-Glucose Cotransporter-2 Inhibitors	20
Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin	20
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock	20
Transfer to Hub Hospitals and Outcomes in Cardiogenic Shock	20
Pulsus Alternans in Cardiogenic Shock Recapitulated in Single Cell Fluorescence Imaging of a Patient’s Cardiomyocyte	19
Defining the Specific Skeletal Muscle Adaptations Responsible for Exercise Training Improvements in Heart Failure With Preserved Ejection Fraction	19
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure	19
SGLT2 Inhibitor–Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event	19
Cardiorenal Syndrome: An Evolutionary Appraisal	18
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure	18
Patient Perceptions and Knowledge Surrounding Pregnancy After Heart Transplantation: A Multicenter Study	18
Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations	18
Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study	18
Comparison of Blood Volume Profiles in Heart Failure With Preserved and Reduced Ejection Fractions: Sex Makes a Difference	18
NETosis Is an Important Component of Chronic Myocardial Inflammation in Patients With Heart Failure	18
Quantification of Vasoactive Medications and the “Pharmaco-Mechanical Continuum” in Cardiogenic Shock	17
Improving Fairness in the Prediction of Heart Failure Length of Stay and Mortality by Integrating Social Determinants of Health	17
SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure	17
Sex-Associated Differences in the Clinical Outcomes of Left Ventricular Assist Device Recipients: Insights From Interagency Registry for Mechanically Assisted Circulatory Support	17
Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation	17
Unexplained Dyspnea on Exertion: The Difference the Right Test Can Make	17
Racial and Social Vulnerability Hotspots in Premature Heart Failure Mortality Across US Counties	17
Succinylation of SERCA2a at K352 Promotes Its Ubiquitinoylation and Degradation by Proteasomes in Sepsis-Induced Heart Dysfunction	17
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF	16
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy	16
Pulmonary Artery Pressure-Guided Heart Failure Management Reduces Hospitalizations in Patients With Chronic Kidney Disease	16
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update	16
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial	16
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization	16
Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction	16
Are Men and Women That Different?	16
Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score	15
Nitric Oxide–Mediated Coronary Endothelial Function Is Impaired in Patients With Heart Failure With Preserved Ejection Fraction	15
Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction	15
Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care	15
Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies	15
Integrative Multiomics for Prognostic Assessment in Pulmonary Arterial Hypertension	15
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing	15
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial	15
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial	15
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	14
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity	14
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction	14
Outcomes of Combined Heart and Kidney Transplantation Under the New Heart Allocation Policy: A United Organ Network for Organ Sharing Database Analysis	14
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial	14
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction	14
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease	14
Letter by Shah Regarding Article, “Reversible Cause of Heart Failure?”	13
Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant	13
You Are Where You Eat: The Local Environment and Risk of Heart Failure	13
Precision Medicine Is in the Eye of the Beholder	13
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF	13
Combined Loss of Obsc and Obsl1 in Murine Hearts Results in Diastolic Dysfunction, Altered Metabolism, and Deregulated Mitophagy	13
Conceptualizing Liberation From Venoarterial Extracorporeal Membrane Oxygenation	13
Letter by ten Berg et al Regarding Article, “Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Regis	13
Response by Park et al to Letter Regarding Article, “Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to	13
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study	12
Impact of Heart Transplant Allocation Change on Waitlist Mortality and Posttransplant Mortality in Patients With Left Ventricular Assist Devices	12
Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support	12
Treatment With Myosin Inhibitor in a Patient With Symptomatic Hypertrophic Cardiomyopathy With Isolated Right Ventricular Obstruction	12
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease	12
Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices	12
Response by Jentzer et al to Letters Regarding Article, “Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock”	12
Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves	12
Abnormal Left Atrial Strain by CMR Is Associated With Left Heart Disease in Patients With Pulmonary Hypertension	12
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction	12
Response by Glargaard et al to Letter Regarding Article, “Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure”	12
Response by Reddy to Letter Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	11
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study	11
Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy	11
Changes in Heart Transplant Listings by Insurance and Race During the COVID Public Health Emergency	11
Right Ventricular Function, Inflammation, and the Gut Microbiome in Pulmonary Hypertension: A Translational Frontier	11
Continuous-Flow Intra-Aortic Percutaneous Mechanical Circulatory Support in Heart Failure With Worsening Renal Function	11

Acute Heart Failure Caused by Rupture of Sinus of Valsalva Into Right Atrium in a Patient With Possible Infective Endocarditis After Tricuspid Annuloplasty: A Misdirected Clinical Decision-Making	11
Patients Who Donate Biospecimens for Research Leave a Valuable and Underappreciated Scientific Legacy	11
Correction to: Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction	10
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial	10
Correction to: Response to Letter Regarding Article “Characterizing Gender Differences in Physical Frailty Phenotypes in Heart Failure”	10
Transfusions in Heart Failure and Acute Myocardial Infarction: Novel Data Begets New Questions	10
Combining Minimally Invasive Surgery With Ultra-Fast-Track Anesthesia in HeartMate 3 Patients: A Pilot Study	10
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome	10
Musclin and HFpEF: Unlocking Skeletal Muscle Potential to Improve Exercise Tolerance	10
Editors and Editorial Board	10
Pathological Analysis of T1 Pseudonormalization in the Advanced Stage of Female Fabry Cardiomyopathy	10
Long-Term Trajectories of Left Heart Geometry, Mechanics, and Oxygen Demand After Bariatric Surgery	10